1% Alendronate Gel in Treatment of Chronic Periodontitis Among Smokers
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
Inclusion Criteria
- No use of antibiotics in the preceding 6 months
- Systemically healthy subjects with probing depth (PD) ≥ 5 mm or periodontal attachment level (PAL) ≥ 4 to 6 mm and a radiographical vertical bone loss ≥ 3 mm
- No history of periodontal therapy in preceding last 6 months
- No use of antibiotics in the preceding 6 months
- Systemically healthy subjects with probing depth (PD) ≥ 5 mm or periodontal attachment level (PAL) ≥ 4 to 6 mm and a radiographical vertical bone loss ≥ 3 mm
- No history of periodontal therapy in preceding last 6 months
Exclusion Criteria
- Subjects with known systemic disease
- Those on systemic ALN/bisphosphonate therapy
- Pregnant or lactating females
- ...
- Subjects with known systemic disease
- Those on systemic ALN/bisphosphonate therapy
- Pregnant or lactating females
- Known or suspected allergy to the ALN/bisphosphonate group
- Immunocompromised subjects
- Use of smokeless tobacco in any form,
- Subjects with aggressive periodontitis,
- Alcoholics
Summary
- Conditions
- Chronic Periodontitis
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
Participation Requirements
- Age
- Between 30 years and 50 years
- Gender
- Both males and females
Inclusion Criteria
- No use of antibiotics in the preceding 6 months
- Systemically healthy subjects with probing depth (PD) ≥ 5 mm or periodontal attachment level (PAL) ≥ 4 to 6 mm and a radiographical vertical bone loss ≥ 3 mm
- No history of periodontal therapy in preceding last 6 months
- No use of antibiotics in the preceding 6 months
- Systemically healthy subjects with probing depth (PD) ≥ 5 mm or periodontal attachment level (PAL) ≥ 4 to 6 mm and a radiographical vertical bone loss ≥ 3 mm
- No history of periodontal therapy in preceding last 6 months
Exclusion Criteria
- Subjects with known systemic disease
- Those on systemic ALN/bisphosphonate therapy
- Pregnant or lactating females
- ...
- Subjects with known systemic disease
- Those on systemic ALN/bisphosphonate therapy
- Pregnant or lactating females
- Known or suspected allergy to the ALN/bisphosphonate group
- Immunocompromised subjects
- Use of smokeless tobacco in any form,
- Subjects with aggressive periodontitis,
- Alcoholics
Tracking Information
- NCT #
- NCT02168543
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Dr. Anuj Sharma, BDS, MDS RIMS, Ranchi
- Dr. Anuj Sharma, BDS, MDS RIMS, Ranchi
Get Well Soon